Annexon, Inc. (NASDAQ:ANNX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Annexon in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($1.29) per share for the year. The consensus estimate for Annexon's current full-year earnings is ($0.96) per share.
Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07).
A number of other equities analysts have also recently commented on ANNX. Needham & Company LLC lowered their price target on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright lowered their price target on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.
Check Out Our Latest Stock Report on ANNX
Annexon Trading Down 8.1%
NASDAQ ANNX traded down $0.22 during midday trading on Wednesday, hitting $2.49. The company had a trading volume of 1,047,473 shares, compared to its average volume of 1,495,223. Annexon has a twelve month low of $1.29 and a twelve month high of $7.85. The company has a market capitalization of $273.19 million, a PE ratio of -2.37 and a beta of 1.26. The firm has a 50-day moving average price of $1.93 and a 200-day moving average price of $3.09.
Hedge Funds Weigh In On Annexon
A number of institutional investors have recently modified their holdings of ANNX. Alpine Global Management LLC bought a new position in Annexon in the first quarter valued at about $49,000. Forefront Analytics LLC raised its position in Annexon by 74.0% in the first quarter. Forefront Analytics LLC now owns 28,591 shares of the company's stock valued at $55,000 after purchasing an additional 12,158 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Annexon in the fourth quarter valued at about $59,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Annexon by 164.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,026 shares of the company's stock valued at $66,000 after purchasing an additional 21,143 shares during the last quarter. Finally, Hsbc Holdings PLC raised its position in Annexon by 19.9% in the first quarter. Hsbc Holdings PLC now owns 36,935 shares of the company's stock valued at $73,000 after purchasing an additional 6,136 shares during the last quarter.
Annexon Company Profile
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Recommended Stories
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
